Overview

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Status:
Not yet recruiting

Trial end date:
2029-10-01

Target enrollment:

Participant gender:

Summary

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol A is a phase I/II trial evaluating the safety and efficacy of Decitabine / Venetoclax and Navitoclax in children and AYA with R/R pediatric ALL/LBL

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Princess Maxima Center for Pediatric Oncology

Collaborators:

Fight Kids Cancer
IBFM
Innovative Therapies For Children with Cancer Consortium

Treatments:

Decitabine
Navitoclax
Venetoclax